Showing 2,141 - 2,160 results of 113,718 for search '(( 12 we decrease ) OR ( 5 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.10s Refine Results
  1. 2141
  2. 2142
  3. 2143

    The decrease of C/EBPα protein during apoptosis involves induction of protein degradation and inhibition of transcription. by Meng Zhao (54299)

    Published 2009
    “…Then, C/EBPα protein was detected with β-actin as a loading control. Folds of decrease of C/EBPα protein/β-actin ratios against untreated cells are shown as means±SD of three independent experiments. …”
  4. 2144
  5. 2145
  6. 2146
  7. 2147
  8. 2148
  9. 2149
  10. 2150
  11. 2151
  12. 2152

    Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice by Cristina Sastre (503532)

    Published 2013
    “…</p><p>Methods</p><p>We evaluated whether hyperlipidemia modulates Klotho expression in kidneys from C57BL/6 and hyperlipidemic apolipoprotein E knockout (ApoE KO) mice fed with a normal chow diet (ND) or a Western-type high cholesterol-fat diet (HC) for 5 to 10 weeks, respectively.…”
  13. 2153
  14. 2154

    Regulatory B10 cells are augmented and the level of IL-10 expression is decreased in the spleen of AD mice. by Jieqiong Li (327149)

    Published 2015
    “…<p>(A) Representative dot-plots showing the percentage of CD5<sup>+</sup>CD19<sup>+</sup>CD1d<sup>hi</sup> B10 cells in control (n = 10) and AD mice (n = 10); (B) Bar graph depicting the percentage of CD5<sup>+</sup>CD19<sup>+</sup>CD1d<sup>hi</sup>B10 cells in control and AD mice as analyzed by flow cytometry. …”
  15. 2155
  16. 2156

    Table_1_Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease.docx by Ziyi Chen (458298)

    Published 2021
    “…Specifically, the expression of pro-inflammatory and chemotactic genes (IL1B, IL13, IL8, and CCL4) was increased in pGD, whereas Th17 and Treg cells associated genes (RORC, CARD9, STAT5A, and SATB1) decreased in pGD. Additionally, TCR diversity was negatively correlated with the expression of pro-inflammatory or chemotactic genes (FASLG, IL18R1, CCL24, and CCL14). …”
  17. 2157

    Image_3_Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease.tif by Ziyi Chen (458298)

    Published 2021
    “…Specifically, the expression of pro-inflammatory and chemotactic genes (IL1B, IL13, IL8, and CCL4) was increased in pGD, whereas Th17 and Treg cells associated genes (RORC, CARD9, STAT5A, and SATB1) decreased in pGD. Additionally, TCR diversity was negatively correlated with the expression of pro-inflammatory or chemotactic genes (FASLG, IL18R1, CCL24, and CCL14). …”
  18. 2158

    Image_1_Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease.tif by Ziyi Chen (458298)

    Published 2021
    “…Specifically, the expression of pro-inflammatory and chemotactic genes (IL1B, IL13, IL8, and CCL4) was increased in pGD, whereas Th17 and Treg cells associated genes (RORC, CARD9, STAT5A, and SATB1) decreased in pGD. Additionally, TCR diversity was negatively correlated with the expression of pro-inflammatory or chemotactic genes (FASLG, IL18R1, CCL24, and CCL14). …”
  19. 2159

    Image_2_Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease.tif by Ziyi Chen (458298)

    Published 2021
    “…Specifically, the expression of pro-inflammatory and chemotactic genes (IL1B, IL13, IL8, and CCL4) was increased in pGD, whereas Th17 and Treg cells associated genes (RORC, CARD9, STAT5A, and SATB1) decreased in pGD. Additionally, TCR diversity was negatively correlated with the expression of pro-inflammatory or chemotactic genes (FASLG, IL18R1, CCL24, and CCL14). …”
  20. 2160

    Table_5_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”